Stopped: Post Market Study terminated early due to the launch and subsequent incorporation of the study into the Terumo Aortic Endovascular Registry (TiGER-001).
This is an EU sponsored trial and independent of the US trial registered under Clinicaltrials.gov ID NCT02009644. The purpose of this registry is to gather clinical data on the safety and performance of the TREO Stent-Graft in patients with infrarenal abdominal aortic aneurysms. The registry is part of TREO's EU post-market surveillance plan providing long-term systematic clinical follow-up.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Aneurysm-related mortality
Timeframe: 30 days post-procedure
Stroke (excluding transient ischemic attack)
Timeframe: 30 days post-procedure
Myocardial infarction
Timeframe: 30 days post-procedure
Renal failure
Timeframe: 30 days post-procedure
Respiratory failure
Timeframe: 30 days post-procedure
Paraplegia
Timeframe: 30 days post-procedure
Bowel ischemia
Timeframe: 30 days post-procedure
Treated aneurysm rupture
Timeframe: 30 days post-procedure